An orally bioavailable small-molecule active-site inhibitor of the phosphatases PTPN2 and PTPN1, ABBV-CLS-484, demonstrates immunotherapeutic efficacy in mouse models of cancer resistant to PD-1 blockade.

Comments

You must log in or register to comment.

(ーー゛)

There's nothing here…

44 points (+44, −0)

Short URL:

http://blurb.social/69443

Health

Welcome to /f/health! This blurb is dedicated to all aspects of well-being. Join discussions on physical and mental health, nutrition, fitness, and medical advancements. Our rules: 1. Be respectful. 2. Stay on topic. 3. Provide reliable sources. 4. Avoid medical advice. 5. No self-diagnosis or promotion. Engage in informed discussions and explore the world of health with us!

Created June 22, 2023
Subscribe via RSS

Moderators

joeyrobert

See full list